About Genor BioPharma
Genor BioPharma is an innovation-driven biopharmaceutical company founded in 2007 with its operating and R&D centre in Shanghai, China. The company focuses on the discovery, development and commercialization of therapeutic antibodies, and its holding company is listed on the Hong Kong Stock Exchange (6998.HK). Its stated mission is to provide innovative therapeutics first to patients in China and gradually to patients worldwide.
Its pipeline centres on monoclonal antibodies, Fc-fusion proteins and bispecific and multi-specific antibodies aimed at oncology — with programmes in breast, lung and gastrointestinal cancers — and autoimmune diseases. Projects include tri-specific molecules targeting CD3, BCMA and GPRC5D for multiple myeloma and a PD-1/CTLA-4/VEGF tri-specific antibody, alongside candidates built on proven targets with strong commercial potential.
Genor has integrated capabilities spanning antibody discovery — including a bispecific discovery platform in San Francisco — CMC development at its Shanghai centre, manufacturing of preclinical and clinical materials, and advanced analytical, quality control and quality assurance systems. This end-to-end structure allows it to advance its own candidates and to collaborate with international partners on licensing and co-development.
Its pipeline centres on monoclonal antibodies, Fc-fusion proteins and bispecific and multi-specific antibodies aimed at oncology — with programmes in breast, lung and gastrointestinal cancers — and autoimmune diseases. Projects include tri-specific molecules targeting CD3, BCMA and GPRC5D for multiple myeloma and a PD-1/CTLA-4/VEGF tri-specific antibody, alongside candidates built on proven targets with strong commercial potential.
Genor has integrated capabilities spanning antibody discovery — including a bispecific discovery platform in San Francisco — CMC development at its Shanghai centre, manufacturing of preclinical and clinical materials, and advanced analytical, quality control and quality assurance systems. This end-to-end structure allows it to advance its own candidates and to collaborate with international partners on licensing and co-development.